nference, a Cambridge, MA-based company on a mission to synthesize the exponentially growing biomedical knowledge has raised $11 million in Series A funding led by Matrix Partners. The round also included participation from existing investor Matrix Capital Management. The company plans to utilize the funding to develop the company’s AI and R&D platforms, expand scientific operations in Cambridge MA and establish nference Labs in Bangalore, India.Founded by Murali Aravamudan and Venky
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
Vanderbilt University to Use $65M to Support Innovative Life Sciences Research
Deerfield Management and Vanderbilt University announced today the launch of Ancora Innovation, LLC ("Ancora"), a Deerfield company that will support Vanderbilt's innovative life science research and leverage Deerfield's expertise in accelerating state-of-the-art drug development. Ancora will fund projects with the aim of changing the current paradigm of drug development and establishing novel therapeutics to cure life-altering diseases.As part of Ancora, Deerfield will commit up to $65 million
Read More
AI-Driven Drug Discovery Startup twoXAR Lands $10M for Computational Platform
twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, announced today that it has raised $10 million in Series A financing led by SoftBank Ventures including follow-on participation from seed investor Andreessen Horowitz. The biotech startup plans to use the funding to build the company’s drug pipeline through partnerships and accelerate preclinical development of existing candidates. Traditional drug discovery and development is estimated to take 10-15 years and
Read More
Atomwise Raises $45M for Artificial Intelligence Platform for Drug Discovery
Atomwise, a San Francisco, CA-based company that develops artificial intelligence systems for drug discovery has raised $45 million in Series A funding led by Monsanto Growth Ventures, B Capital Group and Data Collective. Prior investors Y Combinator, Khosla Ventures, and DFJ also participated in this Series A financing, along with new investors Baidu Ventures, Tencent, and Dolby Family Ventures. The oversubscribed round brings Atomwise’s total capital raised to more than $51 million.Founded in
Read More
Engine Biosciences Lands $10M for AI-Driven Drug Discovery Platform
Engine Biosciences("Engine"), a San Francisco, CA-based biotech company pioneering its artificial intelligence and genomics network biomedicine platform for drug discovery has raised $10 million. The seed round was co-led by by DHVC (Danhua Capital) and 6 Dimensions Capital, with participation from global biopharmaceutical leader WuXi AppTec, EDBI, Pavilion Capital, Baidu Ventures, WI Harper, and Nest.Bio Ventures.The company plans to utilize the funding to support its proprietary platform,
Read More
Sanofi, TriNetX Partner to Optimize Clinical Trials with Digital Technology
TriNetX, the global health research network for healthcare organizations, biopharmaceutical companies, and Contract Research Organizations (CROs), announced their collaboration with their client, Sanofi, a global life sciences company committed to improving access to healthcare via the continuum of care.TriNetX/Sanofi Partnership DetailsClinical trials are a critical component of drug discovery and development, yet the time to market for drugs hasn’t improved significantly in nearly two decades.
Read More
Precision Medicine Group Raises $275M to Support Biomarker-Guided Drug Development
Precision Medicine Group (PMG), an integrated team of experts focused on biomarker-guided drug development has raised $275 million in funding led by Berkshire Partners and TPG Growth and also includes significant participation from Precision’s co-founders and management team as well as original investors Oak Investment Partners and J.H. Whitney. . This investment will support the expansion of PMG’s global footprint and provide additional scale to accelerate the development, approval and
Read More
Pfizer Spin Off Lands $103M to Develop New Drugs for Undeserved Patient Populations
SpringWorks Therapeutics, a new Pfizer spin-off launched as a way to advance investigational drug therapies that may hold significant promise for underserved patients has raised $103 million in funding in Series A funding. The Series A round was led by Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed, Pfizer and LifeArc (formerly known as MRC Technology). SpringWorks Therapeutics’ collaborative business model is designed to deliver both social and financial returns via
Read More
Accenture, Biogen, 1QBit Launch Quantum Computing App to Accelerate Drug Discovery
Accenture and Biogen have developed a first-of-a-kind quantum-enabled molecular comparison app designed to speed up drug discovery for complex neurological conditions such as MS, Alzheimer’s, Parkinson’s and Lou Gehrig’s disease. Researchers at Accenture Labs collaborated with 1QBit to create the new application which enhances Biogen’s existing molecule comparison method with quantum capabilities.Molecular comparison is a crucial part of early-phase drug design and discovery, and involves
Read More
20 Promising Canadian Digital Health Companies to Watch
“A company’s odds of success are better the closer they can get to their market,” argues Stephen Hurwitz, a thought leader in the Canadian venture capital industry, recognizing that the proximity to a VC-tech hub can help the success rate of Canadian startups.
A socialized healthcare system, Canada’s market is fragmented by province and type of care – most primary and emergency care is free for residents whereas specialty care, prescription drugs, long-term and in-home care amongst others,
Read More
